Compare Gilead Sciences, Inc. (GILD) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Realty Income Corp — how do they compare? Gilead Sciences, Inc. trades at $133.61 (market cap $163.51B), while Realty Income Corp trades at $65.09 (market cap $58.99B). The key difference: Gilead Sciences, Inc. is far larger — about 2.8× Realty Income Corp's market cap, and Realty Income Corp pays the higher dividend (5.14%). Which is the better fit depends on your goals.
| GILD | O | |
|---|---|---|
Market Cap | $163.51B | $58.99B |
Sector | Health | Real Estate |
52-Week High | $155.80 | $67.56 |
52-Week Low | $108.22 | $55.93 |
Enterprise Value | $178.05B | $88.79B |
Dividend Yield | 2.49% | 5.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Realty Income (O) trades at $65.04, up 1.99% on the day, near its consensus price target of $67.50. The stock shows bullish technical signals with strong moving averages and support at $63. Recent earnings have missed expectations for three consecutive quarters, though revenue grew to $5.75B in 2025. The company maintains a high gross margin of 92.54% and recently expanded its credit facilities to $5.5B, supporting growth initiatives.
Outlook remains cautiously optimistic with 41% analyst buy ratings, but elevated P/E of 51.85 and consistent earnings misses pose valuation risks. Dividend stability and liquidity improvements provide income investor appeal, yet debt levels rising to 39.93% of assets require monitoring. The stock offers steady income but faces pressure to meet earnings forecasts for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
